2023-505266-29-00招募中2 期
FIPO23 Phase I/II, multi center, Open Label, First-in-human, Dose Escalation and Expansion study to investigate the Safety, Pharmacokinetics, and anti-tumors efficacy of the glyco-humanized polyclonal antibody XON7 in patients with advanced or metastatic solid tumors.
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- Xenothera
- 入组人数
- 246
- 试验地点
- 5
研究概览
简要总结
暂无简介。
入排标准
- 年龄范围
- 18 years 至 65+ years（65+ Years, 18-64 Years）
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究者
Medical Director
Scientific
Xenothera
研究点 (5)
Loading locations...
相似试验
进行中（未招募）
3 期
A Phase 3 Study of ALXN2060 in Participants with Symptomatic Transthyretin Amyloid Cardiomyopathy (ATTR-CM).Transthyretin Amyloid Cardiomyopathy (ATTR-CM)ATTR-CMJPRN-jRCT2071200059Ishioka Tatsunari22
进行中（未招募）
3 期
A clinical study to assess the safety and immunogenicity of Japanese Encephalitis vaccine of BE in 9 to 12 months old infants and in 49-70 year old adultsCTRI/2023/05/053120Biological E.Limited
进行中（未招募）
1 期
Safety and immunogenicity of an additional dose of a candidate recombinant protein vaccine against COVID-19 in people with varying degrees of immunosuppression.EUCTR2022-000785-18-ESHIPRA SCIENTIFIC400
进行中（未招募）
不适用
Clinical trial to test if the study drug is safe and if it works well in severe Type 3 von Willebrand patients that need to have a major surgery.Surgery in Inherited Von Willebrand Disease (VWD)MedDRA version: 14.1Level: PTClassification code 10047715Term: Von Willebrand's diseaseSystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2010-021162-30-ITOCTAPHARMA AG41
进行中（未招募）
不适用
This study in an open label study that is conducted in many centers around the world to investigate whether Wilate is safe and works in patients that need surgery and have von Willebrand disease.Surgery in Inherited Von Willebrand Disease (VWD)MedDRA version: 14.1Level: PTClassification code 10047715Term: Von Willebrand's diseaseSystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2010-021162-30-BGOctapharma AG41